NASDAQ · Health Information Services · USD
Certara, Inc. (CERT) Stock Analysis
Certara, Inc. (CERT) is a Health Information Services stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
CERT Key Statistics
As of Oct 21, 2026Trading
- Open
- $9.67
- Previous Close
- $9.79
- Day's Range
- 9.47–10.29
- 52-Week Range
- 4.45–12.94
- Volume
- 1.72M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.43
Valuation
- Market Cap
- $1.46B
- P/E Ratio
- unprofitable
- Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
- 24.52
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 3.47
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.14
Financials (FY)
- Revenue (FY)
- $418.84M+8.75%
- Net Income (FY)
- −$1.60M
- Profit marginThe share of revenue left as profit after all costs and taxes.
- −16.22%
- Shares Outstanding
- 152.54M
- 1-Year Return
- −17.03%
Dividend and dates
- Earnings Date
- November 5, 2026
- Avg Volume
- 3.08M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, CERT closed at $10.18, −17.03% over 1 year.
Certara, Inc. (CERT) has a market capitalization of $1.46B.
In fiscal 2025, CERT reported revenue of $418.84M.
CERT Stock Return by Calendar Year
Certara, Inc. (CERT) return since Dec 2020: what $10,000 became
- 1 year
- $10,000 $8,297
- −17.03%
- 5 years
- $10,000 $2,639
- −73.61%
- Since Dec 2020
- $10,000 $2,673
- −73.27%
If you had invested $10,000 in Certara, Inc. (CERT) at the close on December 11, 2020, the earliest close on record here, it would have been worth $2,673 at the close on October 21, 2026: −73.27% in total, −20.16% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +15.55% |
| 2025 | −17.28% |
| 2024 | −39.45% |
| 2023 | +9.46% |
| 2022 | −43.46% |
| 2021 | −15.72% |
| 2020 (partial year) | −11.45% |
As of October 21, 2026.
CERT Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $418.84M | −$1.60M | −0.4% |
| 2024 | $385.15M | −$12.05M | −3.1% |
| 2023 | $354.34M | −$55.36M | −15.6% |
| 2022 | $335.64M | $14.73M | 4.4% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $418.84M | $257.71M | $21.02M | −$1.60M | −0.4% |
| 2024 | $385.15M | $230.63M | −$1.73M | −$12.05M | −3.1% |
| 2023 | $354.34M | $213.32M | $6.21M | −$55.36M | −15.6% |
| 2022 | $335.64M | $203.07M | $32.52M | $14.73M | 4.4% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
CERT Valuation vs Health Information Services Median
Median of 44 stocks| Metric | CERT | Health Information Services median | vs median |
|---|---|---|---|
| P/S ratio | 3.47 | 2.31 | 51% above |
| Profit margin | −16.22% | −7.55% | 8.7 pts below |
Medians across 44 Health Information Services stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
Keybanc Maintains Overweight on Certara, Raises Price Target to $12
BenzingaCertara: Software Bookings Are Improving, But Cash Flow Has Yet To Follow
SeekingAlphaTD Cowen Maintains Buy on Certara, Raises Price Target to $11
BenzingaCertara (CERT) Stock Fair Value Edges Higher As Analysts Weigh Turnaround Progress
YahooBarclays Maintains Equal-Weight on Certara, Raises Price Target to $9
BenzingaIn-Silico Drug Discovery Market Report Now Available: Capitalize on AI-led R&D disruption as revenue surges from $3.3B to $6B by 2030; benchmark Certara, Insilico Medicine, Isomorphic Labs, Exscientia and BenevolentAI to secure share.
Yahoo
All 17 articles ↓Show fewer ↑
UBS Downgrades Certara to Neutral, Maintains Price Target to $10
BenzingaCapitalize on Drug Discovery Informatics: Benchmark Schrödinger, Certara, Dotmatics, Thermo Fisher and BIOVIA to Accelerate R&D ROI and Secure Market Advantage
YahooCapitalize on Biosimulation’s R&D Disruption: Benchmark Certara, Simulations Plus, Dassault Systèmes, Schrödinger and Applied BioMath to Accelerate Drug Pipelines and Secure ROI
YahooCertara (CERT) Slashes Jobs While Doubling Down On Software Growth
YahooThe Bull Case For Certara (CERT) Could Change Following Wider Q2 Loss And Leadership Shake-Up - Learn Why
YahooBarclays Maintains Equal-Weight on Certara, Raises Price Target to $7.5
BenzingaCertara, Inc. 2026 Q2 - Results - Earnings Call Presentation
SeekingAlphaCertara, Inc. (CERT) Q2 2026 Earnings Call Transcript
SeekingAlphaTranscript: Certara Q2 2026 Earnings Conference Call
BenzingaCertara Lowers FY2026 Adj EPS Guidance from $0.35-$0.41 to $0.31-$0.36 vs $0.38 Est; Lowers FY2026 Sales Guidance from $395.000M-$405.000M to $367.000M-$382.000M vs $398.585M Est
BenzingaCertara Q2 Adj. EPS $0.08 Misses $0.09 Estimate, Sales $93.271M Miss $98.392M Estimate
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Health Information Services Stocks
Veeva Systems Inc.
$51.90B
BTSGBrightSpring Health Services, Inc.
$12.40B
TEMTempus AI, Inc.
$12.23B
HNGEHinge Health, Inc.
$9.04B
HQYHealthEquity, Inc.
$8.10B
DOCSDoximity, Inc.
$5.99B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B












